Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vioxx litigation update

Executive Summary

Merck is named as defendant in 2,300 Vioxx-related lawsuits, including 4,600 plaintiff groups alleging personal injuries following the use of the COX-2 inhibitor. The first trials are scheduled for May 23 in Alabama and May 31 in Texas. Merck has $675 mil. in reserve to cover the legal costs associated with the withdrawal of Vioxx in September 2004 (1"The Pink Sheet" Jan. 31, 2005, p. 7)...

You may also be interested in...



Merck Sets $604 Mil. Vioxx Legal Defense Reserve; PR Battles Continue

Merck will take a $604 mil. charge in the fourth quarter to establish a reserve for its defense of Vioxx litigation, an amount roughly equivalent to Singulair quarterly sales

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Topics

UsernamePublicRestriction

Register

PS045725

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel